September 10-13, 2019

Tuesday-Friday

Germantown, MD

The Bioscience Education Center

9:00am-5:00pm

1 Hour Lunch Break

2nd Annual - Expanded to 4 Days

This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex platforms for IO (Akoya Biosciences Phenoptics, Cell IDx, CODEX, CyTOF, MIBI, Ultivue), and two days of  hands-on workshop laboratory performing a real multiplex immunofluorescence staining panel using the Opal™ method, multispectral image acquisition with a Polaris™ scanner, and immunophenotyping analysis using InForm™ and HALO™ software.

symposiumSymposium Lecture Series
Days 2 & 3
hands-on labHands-On Laboratory Workshop
*Limited Availability*
Days 1 & 4
thumbnail driveAll attendees receive a thumbnail drive with Lecture PDFs. Day 2&3 attendees will also receive a comprehensive binder containing workshop material.
ci2Symposium Participants: 85
Hands-On Workshop: Limited to 24 Attendees
ci1Symposium and Hands-On Workshop: $995
Symposium Only: $695

SPONSORS  
Bio-Trac Logo

Cancer immunotherapy represents an ongoing revolution in cancer treatment that requires a deeper understanding of the tumor immunological microenvironment. One of the tools for cancer immunoprofiling on tissues is multiplex immunohistochemistry/immunofluorescence (IF) techniques for the labeling of several markers on the same tissue slide. One of such techniques is the Opal™ method, coupled with Vectra – Polaris™ multispectral scanner, both developed by PerkinElmer, which allows the design of customizable multiplex IF panels for immuno-oncology studies.

2019 Speakers

Bernard A. Fox, PhD, Keynote
Providence Portland Medical Center
A Vision for Tailoring Cancer Immunotherapy and the Hurdles Ahead
Mike Angelo, MD PhD
Stanford University
Comprehensive Enumeration of Immune Cells in Solid Human Tissue using Multiplexed Imaging
Carlo Bifulco, MD
Providence Portland Medical Center
From mIHC/IF to H&E. Back to the Future
Edwin Parra Cuentas MD, PhD
MD Anderson Cancer Center
Profiling Immune Contexture in the Era of Multiplexed Staining and Immune Oncology
Sean Downing
Ultivue
Phenotyping the Tumor Microenvironment with Advanced Tissue-based Multiplexing Assays
Cliff Hoyt, MS
Akoya Biosciences
Translational Advances of Multiplexed Immunofluorescence Methods
saterHoussein Abdul Sater, MD
NIH/NCI
Prostate Tumor Immune Microenvironment Multiplexed and Spatially Resolved
Kurt Schalper, MD, PhD
Yale University School of Medicine
Deciphering the Tumor and Immune-cell Interactions in Human Malignancies Using Multiplexed and Spatially Resolved Imaging
Dr. Janis Taube
Johns Hopkins Medical Institute
Intensity In-situ
Sarah Warren, PhD
NanoString Technologies
Characterization of The Tumor Microenvironment with the NanoString GeoMx Digital Spatial Profiling Platform
Jaime Rodriguez-Canales, MD
Senior Pathologist AstraZeneca
Course Director
Michael Surace, PhD
Scientist, AstraZeneca
Workshop Director

Check back for updates on lecture topics and speaker additions.

Hands-on Laboratory - 2 Days

•             Panel Planning, Run and Development Controls

•             Sample Prep and OPAL 6+1 Fluorescent Multiplex on Bond Rx (Leica)

•             Image Acquisition on Vectra Polaris (Akoya Biosciences)

•             Spectral Unmixing and Quality Control

•             Image Analysis of Whole Slide 6+1 plex with HALO (Indica Labs)

Presenter Bios


Bernard A. Fox, PhD, Keynote

  • Harder Family Chair for Cancer Research
  • Member and Chief, Laboratory of Molecular and Tumor Immunology
  • Robert W. Franz Cancer Center
  • Earle A. Chiles Research Institute, Providence Portland Medical Center

Dr. Fox is an internationally recognized leader in immuno-oncology and co-founder and CEO of UbiVac who has spent more than 30 years studying how to use a patient’s immune system to fight cancer. Dr. Fox has participated in and led both preclinical and clinical studies of cancer immunotherapy. Building on recent advances in immunology and the Nobel prize-winning science of autophagy, he is utilizing the disruptive innovation of UbiVac’s vaccine technology to advance treatments for patients with many types of cancer. He is also driving UbiVac’s efforts, in collaboration with Janssen Biotech (J&J), to develop vaccines that prevent cancer. Dr. Fox also holds the Harder Family Chair for Cancer Research, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center and is on faculty at OHSU. His background in translational cancer immunotherapy developed from his tenure as a fellow in Dr. Steven Rosenberg’s lab at the National Cancer Institute.

In addition to training a next generation of scientists and physicians, Dr. Fox is the current Chair of the World Immunotherapy Council, a consortium of 22 national and international cancer immunotherapy organizations and a past President of the Society for Immunotherapy of Cancer. He has published more than 130 manuscripts and book chapters, served on review committees for the NIH, FDA, philanthropic and governmental organizations in the USA, Europe and Asia, and serves on editorial boards of several scientific journals. Dr. Fox served on the board of directors of NeoPharm from 2004 to 2010, and is currently on the board of directors of the Oregon Bioscience Association. In 2011, Dr. Fox co-founded UbiVac-CMV, to develop cytomegalovirus vectors as vaccines for cancer. Dr. Fox lectures widely and serves on advisory boards for a number of biotechnology and pharmaceutical companies. In 2015, Dr. Fox received the Visionary/Legacy Award from the Society for Immunotherapy of Cancer (SITC).


Michael R. Angelo, Stanford University

The Angelo lab uses custom built high dimensional imaging technologies and computational approaches to understand the interplay between single cell phenotype and tissue histology in health and disease.

They employ a method known as Multiplexed Ion Beam Imaging (MIBI) that uses secondary ion mass spectrometry to image antibodies tagged with isotopically pure elemental metal reporters. MIBI is capable of analyzing up to 100 targets simultaneously over a five-log dynamic range. Thus, MIBI enables highly multiplexed and sensitive immunohistochemistical analysis of complex tissues. The Angelo Lab applies MIBI to questions in the fields of cancer biology, infectious diseases, immune tolerance, allergy, and the maternal-fetal interface in addition to technology and methods development.


Carlo B. Bifulco, M.D, Providence Portland Medical Center

Dr. Bifulco received his medical training at the State University of Milan, Italy. He served an internship in Internal Medicine at Griffin Hospital of Yale University prior to a Residency in Anatomic Pathology at Yale New Haven Hospital. Dr. Bifulco served Fellowships in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center in New York, and in Hematopathology at Yale University. He was an attending Pathologist at the National Cancer Institute in Milan, Italy, while also serving as Director of the Laboratory of Molecular Genetic Pathology. Prior to joining Providence Pathology, Dr. Bifulco served on the Pathology faculties at the University of Florida and at Yale University. Dr. Bifulco is currently the Medical Director of Oncological Molecular Pathology and Pathology Informatics at the Providence Oregon Regional Laboratory and the Director of Translational Molecular Pathology at the Earle A. Chiles Research Institute.


Cliff Hoyt, MS, PerkinElmer

Mr. Hoyt runs PerkinElmer’s quantitative pathology applications and services, and supports senior management as a technology strategist in the area of oncology, helping to identify clinical opportunities for the Vectra and Opal platform. This includes establishing and managing collaborations and partnerships with academic and industrial institutions, and managing an applications group on the PerkinElmer Hopkinton site to develop methods. Mr. Hoyt joined PerkinElmer through the acquisition of CRI, Inc., of which he was a founder. Over the course of his career, he has been principle investigator on a number of NIH research grants, and played a key role in the development and commercialization of several innovative technologies and products, including metrology instruments, laser controllers, telecommunications components, imaging systems for in vitro fertilization, and in vivo and pathology imaging systems, which is his main focus today. Mr. Hoyt received a BA in physics from Williams College in 1983 and Master’s in mechanical engineering from the Massachusetts Institute of Technology in 1987. He is a named inventor on over 20 patents.


Edwin Parra, MD, PhD, MD Anderson Cancer Center

Dr Parra is Assistant Professor and director of the laboratory of multiplex immunofluorescence and image analysis in the Department of Translational Molecular Pathology, at the University of Texas - MD Anderson Cancer Center, Houston, TX.  He was trained as research and molecular pathologist with an specialization in lung pathology at the University of Sao Paulo, Brazil.  In 2013, Dr. Parra joined Dr. Ignacio Wistuba’s lab at the MD Anderson Cancer Center where he worked setting up multiplex IF using the Vectra -Polaris systems.  Dr. Parra has published over 86 peer-reviewed papers, including several publications employing multiplex IF and Vectra for cancer immunoprofiling.


Jaime Rodriguez-Canales, M.D., AstraZeneca

Jaime Rodriguez-Canales received his M.D. degree and Anatomic Pathology board certification at the Pontifical Catholic University of Chile (Santiago, Chile). Dr. Rodriguez is also certified by the European Board of Pathology (Utrecht, the Netherlands). From 2002 to 2005 he was fellow in oncologic surgical pathology under the direction of Dr. Juan Rosai, in Milan, Italy. From 2005 to 2012, Dr. Rodriguez was postdoc visiting fellow and research fellow at the Pathogenetics Unit and Laser Capture Microdissection (LCM) Core at the Laboratory of Pathology, National Cancer Institute, NIH. In 2012, Dr. Rodriguez joined Dr. Ignacio Wistuba’s lab at the University of Texas – MD Anderson Cancer Center (Houston, TX) being promoted in 2013 to Assistant Professor and Director of the Immunohistochemistry & Digital Pathology lab of the Department of Translational Molecular Pathology, where he and his team worked optimizing multiplex IHC and Vectra for cancer immunoprofiling. In August 2017, Dr. Rodriguez moved back to Maryland as Senior Pathologist at MedImmune, where he continues to work on multiplex IHC and Vectra - Polaris for immuno-oncology. Dr. Rodriguez has co-authored over 125 peer-reviewed papers, including a study on validation of multiplex IF and multispectral analysis for cancer immunoprofiling (Sci Rep. 2017). Dr. Rodriguez is member of the United States and Canadian Academy of Pathology (USCAP), American Association for Cancer Research (AACR) and the Society for Cancer Immunotherapy (SITC).


Houssein Abdul Sater, M.D., National Cancer Institute

After graduating from the Lebanese University Faculty of Medical Sciences and training for 2 years in surgical pathology, Dr Sater was awarded a Fosfom 2 year scholarship in onco-pathology at the Free University of Brussels (ULB), Belgium. He then trained in the US and graduated as a hematologist-oncologist from the Medical College of Georgia. His research involved work on post translational modifications of FOXP3 protein and more recently focused on identifying clinically relevant biomarkers through multiplex IHC platforms. He joined the National Institute of Health through Leidos in late 2017 to lead the GU malignancies branch immune correlative studies. He has published some of his work in lung, and breast cancer with ongoing work on neoadjuvant prostate cancer.


Kurt Schalper, MD, PhD, Yale University School of Medicine

Dr. Schalper trained as cell/molecular biologist and surgical pathologist. His professional experience includes molecular diagnostics and measurement of tissue biomarkers for companion diagnostics in cancer. Currently, he is an Assistant Professor of Pathology at Yale University and director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center. His group aims to produce and support high quality translational research in immuno-oncology through standardized analyses of biomarkers and cross-integration with other Yale resources. These efforts could open new opportunities for biomarker discovery, identification of targets and patient selection for novel anti-cancer therapies.


Michael Surace, PhD, AstraZeneca

Michael Surace received a BS in Biology from JMU in 2004 before working as a laboratory technician in Pathology at UVA for two years. In 2006 he moved to Blacksburg, VA to pursue graduate studies in nuclear receptor/ TLR cell signaling crosstalk in the polarization of macrophage activation phenotypes. He received his PhD from Virginia Tech in 2010. He took two postdocs at MCV in Richmond, first in the Department of Anatomy and Neurobiology investigating the role of microglial activation in response to toxic insult in Parkinson’s Disease, then in Molecular Biology and Biochemistry, working on astrocytes as inflammatory immune cells in multiple sclerosis. In 2015 he joined STCube Pharmaceuticals as a research scientist where he started working with multiplex immunofluorescesce and image analysis to support mechanistic research, which led to his current position at Medimmune, as a scientist developing the company’s multiplex immunofluorescence program for research and clinical trials.


Dr. Janis Taube,  Johns Hopkins Medical Institute

Dr. Janis Taube is an associate professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine.
She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. Her research is related to the study of the B7-H1 molecule. Dr. Taube and her team are seeking to identify the signaling mechanisms behind B7-H1 expression.
She is a member of the College of American Pathologists, United States and Canadian Academy of Pathology, American Society of Dermatopathology and Dermatology Foundation.


Sarah Warren, PhD, NanoString Technologies

Sarah Warren is the Director of Advanced Applications and Immuno-Oncology at NanoString Technologies, where she leads a team of researchers who work on a wide variety of projects to apply NanoString technologies, including GeoMx, to critical questions in immuno-oncology via collaborations with academic investigators and biopharma partners as well as in-house research. She has a PhD in immunology from the University of Washington and previously was a founder and director of research at Oncofactor Corp.

The Bioscience Education Center

Montgomery College
20200 Observation Drive
Germantown, MD 20876